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ABSTRACT
Background: To evaluate the diagnostic performance of [18F]fluorodeoxyglucose positron emission tomography/computed 
tomography ([18F]FDG-PET/CT) scan in detecting local recurrences in patients with surgically treated oral tongue squamous 
cell cancer (OTSCC).
Material and methods: Eighty-seven patients who had undergone surgery for OTSCC were monitored clinically and [18F]FDG-
PET/CT and magnetic resonance (MR). PET uptakes were classified as functional (Type A), suspicious (Type B), or highly 
suggestive of local recurrence (Type C). A multidisciplinary team (MDT) evaluated case-by-case the surveillance strategy based 
on PET uptake.
Results: Fifty-nine patients presented FDG-PET uptake during follow-up: this report was significantly more frequent in patients 
who received flap reconstruction than in those without (73% vs 50%; p = 0.05). In 13 patients with Type A (n = 1), Type B 
(n = 9), and Type C (n = 3) uptakes an additional MR was considered preferable and discovered recurrence in 12.PET-CT had 
9 true positives, 17 false positives, 71 true negatives, and no false-negative, resulting in sensitivity, specificity, positive (PPV) 
and negative predictive values (NPV) of 100%, 80.7%, 34.6%, and 100%. 
Conclusions: The present results demonstrated a change in diagnostic strategy, as decided by the MDT, in about one-fifth of 
patients. The results should prompt in designing a rational surveillance schedule in surgically treated OTSCC.
KEY words: tongue carcinoma; PET/CT; [18F]FDG PET/CT; magnetic resonance imaging
Nucl Med Rev 2021; 24, 2: 58–62
Correspondence to: Domenico Albano
Department of Nuclear Medicine, University of Brescia, Brescia, Italy
e-mail: doalba87@libero.it
Introduction
The incidence of oral tongue squamous cell carcinoma 
(OTSCC) is increasing worldwide and, although the peak is seen 
around the 6th decade, there is evidence of its increasing occur-
rence among the youngest, presumably due to early initiation of 
smoking habits and alcohol consumption [1–3]. The therapeutic 
management of this type of tumour has not changed substantially 
in the last few decades and mainly relies on surgery alone for early 
T categories, while multimodal approaches (surgery followed by 
radiotherapy [RT] or chemoradiotherapy [CRT]) are applied to 
more advanced lesions. Surgical management of T1-T2 OTSCC 
consists of surgical excision with wide free margins (ranging 
between 1 and 2 cm) [4], while in case of larger tumours with 
a depth of invasion (DOI) superior to 10 mm (staged as T3 or 
higher according to the 8th Edition of the AJCC-UICC TNM Staging 
System) [5] some authors systematically perform a compartmental 
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Patient baseline characteristics, type of treatment delivered, T, N 
and surgical margins features of the primary tumour are detailed 
in Table 1.
Follow-up policy
According to the NCCN guidelines [16], the institutional 
follow-up protocol consisted of clinical examination (every 
2 months for the first 2 years, every 4 months for the third year, 
and then every 6 months until the 5th year) and imaging (PET-CT 
3 months after surgery, MR at 9 months, then, alternatively, PET-CT 
and MR, every 6 months for 2 years and every year until the 5th year).
Patients with suspicious or positive findings at imaging were 
discussed in the multidisciplinary team (MDT) and submitted to:
 — biopsy and PET-CT when a suspect was raised on the routine 
follow-up MR;
 — MR when a suspect was raised on the routine follow-up PET-CT; 
 — watchful-waiting when the level of a suspect on either MR or 
PET-CT was considered low after the MDT review.
Only patients for whom PET-CT and MR studies were avail-
able and with at least 1 year of follow-up were included in the 
present study. The Median follow-up time was 36 months (range 
12–90 months)
hemiglossopelvectomy to improve loco-regional control [6–8]. 
This surgical technique aims to the “en bloc” removal of the entire 
hemitongue and floor of mouth compartment along with its con-
nective, neuromuscular, vascular, and lymphatic structures (also 
known as the T-N tract) connecting it to the adjacent neck levels. 
As a mandatory step after compartmental resection, a free or 
pedicled flap reconstruction is required, which frequently produc-
es a certain degree of distortion of the anatomical configuration of 
the residual hemitongue and floor of the mouth [9, 10]. 
Computed tomography (CT) and magnetic resonance (MR) are 
the imaging modalities of choice in the pretreatment setting [11–14], 
the latter being more sensitive and specific, especially in terms of 
DOI evaluation [15]. According to the National Comprehensive 
Cancer Network (NCCN) guidelines [16] [18F]fluorodeoxyglucose 
positron emission tomography/CT ([18F]FDG-PET/CT) should also 
be considered in the preoperative evaluation of advanced (III–IV) 
stages due to a higher probability of unfavourable scenarios such 
as contralateral and/or lower neck lymph node metastases, and 
distant disease. During OTSCC follow-up, imaging plays also an es-
sential role, especially in the detection of submucosal relapses, 
which may be missed at clinical evaluation. However, the algorithm 
for post-treatment follow-up is still a matter of debate. NCCN 
guidelines assert that annual repetition of the pretreatment imaging 
modality may be indicated in areas difficult to be appropriately visu-
alized on clinical examination. As a general rule, the higher contrast 
resolution of MR is expected to improve the differentiation between 
muscle, scar, flap and recurrent tumour, as compared to CT [17]. 
On the other hand, in a large multicentric study, Mehanna et al. 
[18] demonstrated that [18F]FDG-PET/CT performed 3 months after 
CRT can replace planned neck dissection in a significant number 
of patients thanks to its very high negative predictive value (NPV) 
in assessing nodal metastases. Furthermore, [18F]FDG-PET/CT 
is unsurpassed to rule out distant metastases. 
The role of PET/CT in assessing local control after surgery, 
however, has not been widely investigated. Müller et al. [19] 
compared contrast-enhanced CT, unenhanced PET/CT, and the 
combination of PET and contrast-enhanced CT in the follow-up of 
a small cohort of oral cancer patients after surgical treatment and 
flap reconstruction, finding that a combination of techniques gave 
the best performance in assessing loco-regional control. However, 
the issue of false-positive uptake in the floor of the mouth caused 
by different physiological factors should be considered, as recently 
suggested by Haerle et al. [20]. 
The aim of this study is therefore to investigate the role of 
[18F]FDG-PET/CT in monitoring local control in a cohort of pa-
tients surgically treated for OTSCC.
Material and methods
The local Institutional Review Board approved this retrospective 
observational study.
Patients 
The clinical and follow-up records of 87 patients (56 men, 31 
women; age range, 45–87 years; mean, 67 years) surgically treated 
for OTSCC in the Department of Otorhinolaryngology-Head and 
Neck Surgery of a tertiary referral academic Institution between 
December 2012 and February 2017, were retrospectively reviewed. 
Table 1. Patient baseline characteristics and type of surgery




transoral partial glossectomy 22 (25%)
anterior pelvectomy 3 (3%)
mandibulectomy 3 (3%)
total glossectomy 2 (2%)
Reconstruction flaps n = 68
Radial Forearm free flap 29 (42.5%)
Antero Lateral thigh free flap 26 (38%)
Fibula free flap 3 (4.5%)
Lateral Dorsi free flap 3 (4.5%)
Facial artery myo-mucosal flap 1 (1.5%)
Scapular composite osteocutaneous fla 2 (3%)
Tranverse Rectus Myocutaneous free flap 2 (3%)













*AJCC cancer staging. 8th ed.
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PET-CT imaging and interpretation
PET-CT was performed after at least 6 hours fasting and with 
a glucose level lower than 150 mg/dL. The activity of 3.5–4.5 
MBq/kg of [18F]FDG was administered intravenously and imag-
es were acquired 60 ± 10 minutes after injection of the radiotracer. 
Imaging was from the vertex to the mid-thigh using a Discovery 
690 or a Discovery ST PET-CT system (General Electric Company, 
Milwaukee, WI, USA) with standard parameters (CT: 80 mA, 120 kV 
without contrast; 2.5–4 minutes per bed with a PET-step of 15 cm). 
The reconstruction was performed in a 128 × 128 matrix and with 
a 60 cm field of view. Patients were instructed to void before imag-
ing acquisition, while no oral or intravenous contrast agents were 
administered or bowel preparation used for any patient. PET imag-
es were analysed visually by two nuclear medicine physicians with 
more than 15 years of experience in head and neck imaging. Every 
focal radiotracer uptake different from the physiological distribution 
and higher than background was regarded as suspicious or highly 
suggestive of recurrent disease. In case of discordant opinions, 
a third nuclear medicine physician was consulted. When present, 
PET uptakes in the oral cavity were classified as functional (Type A), 
suspicious (Type B), or highly suggestive of neoplastic recurrence 
(Type C) (Figure 1). In the case of highly suggestive uptakes, MR 
was used to confirm the diagnosis and possibly stage the relapse.
An MDT composed of radiologists, nuclear medicine phy-
sicians, head and neck surgeons, and medical and radiation 
oncologists evaluated each case with PET radiotracer uptake to 
decide whether further diagnostic assessment by MR was neces-
sary. The decision was made in consensus and was based on site 
of uptake, clinical and endoscopic findings, and re-assessment of 
the fusion CT scans.
MR imaging and interpretation
All the examinations were performed on a 1.5 T scanner (Mag-
netomAera, Siemens Healthcare, Erlangen, Germany). The MR 
protocol included: T2-weighted sequences on the axial and coro-
nal planes (and/or sagittal plane, when necessary), T1-weighted, 
diffusion-weighted imaging (DWI), and post-contrast 3D fat-satu-
rated gradient echo (VIBE) on the axial plane; the latter was also 
reconstructed on coronal and sagittal planes.
MR studies were reported by a team of five radiologists with 
extensive experience in head and neck imaging. A recurrence 
was suspected in the presence of nodular lesion with contrast 
enhancement and restriction at DWI. T2 hypointense tissue with 
faint contrast enhancement and no DWI restriction was a scar. 
T2 hyperintense tissue with variable contrast enhancement and 
increased water diffusivity at DWI was inflammatory oedema or 
granulation tissue.
The standard of reference was histology for resected or biop-
sied lesions and long-term follow-up in the case of negative PET-CT 
and MR studies.
Statistical analysis
Descriptive statistics were used for patients’ characteristics, 
type of surgery, and type of PET uptake. The diagnostic perfor-
mance of PET-CT was assessed in terms of sensitivity, specificity, 
PPV, and NPV. A Chi-square test was used to compare the frequency 
of PET uptake in patients with and without reconstruction by pedi-
cled or free flaps. The threshold of statistical significance was set 
at 0.05. Statistical analyses were performed using Medcalc statistic 
software (Mariakerke, Belgium)
Results
A pathological diagnosis of local recurrence was diagnosed in 
9 (10%) patients: in 2 of these (22%), PET-CT identified a subclinical 
local recurrence during routine follow-up while, in the remaining 
7, the recurrence was clinically evident and PET-CT and MR were 
performed just to confirm and appropriately stage the disease.
A total of 208 PET-CT reports were screened in such a cohort 
of 87 patients. In 59 (68%) patients FDG uptake in the oral cavity 
was seen at PET-CT during follow-up; in detail, uptake was present 
in 49 (73%) patients who received flap reconstruction and in 10 
(50%) without (p = 0.05). The characteristics of PET uptake are 
summarized in Table 2.
In 13 (22%) patients with PET uptake in the oral cavity, the MDT 
agreed to change the routine follow-up schedule by prescribing 
an additional MR scan. In 12 (92%) cases, MR was triggered by 
a Type B (9 patients) or Type C (3 patients) uptake. In one patient, 
MR was performed despite the PET uptake having been classified 
as Type A, because of clinical suspicion. In one case of Type C 
uptake, the MDT opted for a surveillance policy due to the pa-
tient’s poor general condition.
Figure 1. A. A representative case of type-A functional FDG uptake 
in the oral cavity (axial PET, PET/CT fused and contrast-enhanced 
images; B. in a 48-year old male treated for left-side tongue cancer. 
An example of type-B suspicious uptake on the left side in a 66-year 
old male treated for tongue carcinoma (axial PET, PET/CT fused and 
T-2 MRI images; C. A case of type-C FDG uptake on the right lip and 
cheek consistent with relapse (axial PET, PET/CT fused and T-2 MRI 
images
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In 12 (92%) cases with PET uptake in the oral cavity, the final 
diagnosis was no recurrence, while in one a recurrence was con-
firmed. In 12 cases, MR agreed with the final diagnosis. In one, MR 
findings were considered suspicious and a short-term follow-up 
was suggested. Long-term follow up confirmed no recurrence 
(one false positive) (Table 2). The single case of Type C uptake in 
which the MDT opted for watchful waiting showed no recurrence 
on long-term follow-up
Diagnostic performance of PET-CT
When considering no uptake and Type-A uptake as negative 
findings, and Type B and C uptake as positive findings, PET-CT 
had 9 true positives, 17 false positives, 71 true negatives, and no 
false-negative, resulting in a sensitivity, specificity, PPV, and NPV 
of 100%, 80.7%, 34.6%, and 100%, respectively. If the 7 cases in 
which PET-CT was used to stage clinically evident recurrences are 
excluded, PPV drops down to 10.5%, while the other statistical 
descriptors remain unchanged. In 13 cases, an inconclusive PET 
triggered an additional MR scan: in 12 of them, the final diagno-
sis turned out to be negative.
Discussion
In the absence of strict indications, even on international 
guidelines, the schedule and results of imaging follow-up of 
OTSCC are variable and largely influenced by factors like the type 
and number of patients treated, local facilities, geographic, and 
economic constraints. Clinical surveillance is universally consid-
ered the mainstay: in some centres, imaging is performed only in 
clinically suspicious cases, whereas in others it is fully integrated 
into the follow-up strategy also of clinically negative patients. In the 
authors’ centre, a scheduled follow-up consisting of clinical exam-
ination and alternating [18F]FDG-PET/CT and MR scans has been 
adopted. The first imaging examination in the follow-up timeline, 
namely [18F]FDG-PET/CT, is performed 3 months after surgery, 
as suggested by the international guidelines, to limit false-positive 
results related to inflammatory changes [16]. 
While confirming the very high NPV of [18F]FDG-PET/CT 
in assessing local recurrences, the results of this study raise 
concerns about the very low PPV caused by the high number of 
false-positive results. Several PET radioisotope uptakes were report-
ed as physiological (Type A) by nuclear medicine physicians experi-
enced in head and neck imaging and were considered negative for 
this analysis. The presence of such physiological uptake has been 
described by Haerle et al. [20], who reported a strong prevalence 
of FDG uptake at the level of the mylohyoid muscle. 
This is probably due to its activation during deglutition which, 
unlike chewing and talking, is an involuntary movement and 
thus cannot be completely avoided during the FDG uptake phase.
The largest portion of Type B PET uptakes (15 out of 59) 
did not determine changes of the standard follow-up protocol 
after discussion within the MDT: based on free pathological 
margins on the specimen, absence of symptoms, and unequiv-
ocally negative clinical evaluation, no additional study was pre-
scribed. Only one (11%) patient with Type B uptake, further 
investigated with an additional MR scan, had a pathologically 
proven diagnosis of recurrence. Moreover, in 4 cases with Type 
C uptake (3 submitted to an additional MR, and once submitted 
to watchful waiting policy) recurrences were negative. These 
results question the possibility to make an accurate distinction 
between pathological and non-pathological uptakes, even in 
a tertiary care hospital with well-equipped nuclear medicine and 
experienced physicians.
In patients with flap reconstruction, among which the inci-
dence of suspicious PET uptakes was significantly higher, the 
most common site for FDG uptake was seen deep in the floor 
of the mouth, near the interface between native tissue and flap. 
Such finding was retrospectively explained as a compensatory 
hyperactivation of the contralateral extrinsic oral muscles which, 
in such a distorted and asymmetric anatomy, may retract the flap. 
In line with these observations, Müller et al. [19] analysed a small 
cohort of 17 oral cancer patients who underwent surgery followed 
by reconstruction to demonstrate the added value of contrast-en-
hanced CT compared with standard FDG-PET with unenhanced 
CT. They found that by using contrast-enhanced CT, the specificity 
increased from 58% to 89%. This suggests that contrast-enhanced 
CT performed simultaneously with PET or as a second step, can 
improve the interpretation of PET findings and help to reduce the 
number of false-positive findings. In the authors’ protocol, only 
plain CT was performed simultaneously with PET. CT images were 
used to assess the presence of solid tissue with mass effect 
at the uptake site but did not provide information about tissue 
vascularization. Although the absence of information provided by 
contrast enhancement may be a limitation of this study, it must be 
emphasized that simultaneous acquisition of PET and contrast-en-
hanced CT is not a routine procedure in most centres (for example, 
it is not feasible with old scanners), and the separate acquisition 
of contrast-enhanced CT or MR as a second step would impact 
on logistics and costs.
In this study, state-of-the-art MR proved to be a very accurate 
technique in clarifying suspicious PET findings and, in most cases, 
ruled out local relapse. This result does not imply an overall su-
periority of MR compared to [18F]FDG-PET/CT as the latter is very 
effective in assessing nodal and distant spread.
Table 2. Summary of types of PET radiotracer uptake, additional MRI 
needed and final diagnoses






Need for additional 
MRI
13/87
9/13 type B uptake
3/13 type C uptake







1/13 positive: type B
1/13 suspicious: type B
The final diagnosis in 
patients with additional 
MRI
12/13 negative (negative MRI or suspicious in 1 
case)
1/13 recurrence (positive MRI)
Nuclear Medicine Review 2021, Vol. 24, No. 2
www.journals.viamedica.pl/nuclear_medicine_review62
Original
The main strength of this study is the relatively large number of 
homogeneously treated OTSCC patients, all followed by the same 
MDT with a PET/CT scan, while its main limitation is represented 
by its retrospective design. Moreover, semiquantitative analysis of 
PET uptake based on standardized uptake value was not performed 
given that, so far, no studies are establishing its usefulness in 
this setting. Despite the above-mentioned limitations, however, the 
results of this study suggest a more rational use of PET/CT, which 
might be reserved to patients with a high risk of distant metasta-
ses or to those in whom, for neck treatment, a watchful waiting 
policy is preferred over prophylactic dissection [18].
In times of economic constraints, a compelling evaluation of the 
real efficacy of a given follow-up policy in cancer patients is man-
datory. For what concerns advanced OTSCC, which is currently 
often treated with all the available therapeutic modalities and recon-
structive techniques, an expensive follow-up based on the liberal 
use of PET-CT (plus clinical examination and MR when needed) 
seems unjustified in terms of clinical benefits.
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